Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovarian screening test proves 100% effective:

This article was originally published in Clinica

Executive Summary

A US study has shown that a potential screening test for ovarian cancer could be 100% effective at detecting the disease early. The test uses high-resolution mass spectrometry (MS) to measure patterns of protein markers in blood. Study researchers, led by Tim Veenstra of the National Cancer Institute at Frederick, in Maryland, said that the technique correctly classified serum obtained from epithelial ovarian cancer patients and healthy patients with a sensitivity and specificity of 100%. Describing their findings in Endocrine-Related Cancer (2004, 11 163-178), the researchers concluded: "Multiple and distinct proteomic patterns, comprising low molecular weight biomarkers, detected by high-resolution MS achieve accuracies surpassing individual biomarkers, warranting validation in a large clinical study."

Topics

UsernamePublicRestriction

Register

MT059228

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel